Caov-4Homo sapiens (Human)Cancer cell line

Also known as: Caov4, CAOV4, CAOV-4, CaOV-4, CaOv-4

🤖 AI SummaryBased on 10 publications

Quick Overview

Human ovarian cancer cell line with potential for research in tumor models.

Detailed Summary

Caov-4 is a human ovarian cancer cell line derived from a tumor, though specific tissue and disease details are not provided. It is used in cancer research, particularly in studies comparing genomic profiles of cancer cell lines to primary tumors. Research indicates that Caov-4 may have characteristics relevant to high-grade serous ovarian cancer (HGSOC), but its exact molecular profile and utility in preclinical studies require further investigation. The cell line is part of a panel used to evaluate genomic similarities and differences between cancer cell lines and primary tumors, aiding in the identification of suitable models for in vitro studies.

Research Applications

Genomic profiling of cancer cell linesComparison of cancer cell lines to primary tumorsIdentification of suitable in vitro models for HGSOC

Key Characteristics

Potential relevance to high-grade serous ovarian cancerPart of a panel for genomic comparison studies
Generated on 6/15/2025

Basic Information

Database IDCVCL_0202
SpeciesHomo sapiens (Human)
Tissue SourceFallopian tube, subserosa[UBERON:UBERON_8480037]

Donor Information

Age45
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseHigh grade ovarian serous adenocarcinoma
LineageOvary/Fallopian Tube
SubtypeHigh-Grade Serous Ovarian Cancer
OncoTree CodeHGSOC

DepMap Information

Source TypeATCC
Source IDACH-000103_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Val147Asp (c.440T>A)Unspecified-PubMed=32321971

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
12,14
D16S539
9,11
D18S51
21
D19S433
11,12
D21S11
28,33.2
D2S1338
17,20
D3S1358
16
D5S818
11
D7S820
8,10
D8S1179
12
FGA
22
Penta D
9,10
Penta E
12,13
TH01
6,9.3
TPOX
8,9
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Noonan A.M., Annunziata C.M.

Gynecol. Oncol. 142:332-340(2016).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Oncol. Rep. 23:1021-1026(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.

Berchuck A., Futreal P.A.

Gynecol. Oncol. 70:13-16(1998).

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

Wright W.C., Daniels W.P., Fogh J.

J. Natl. Cancer Inst. 66:239-247(1981).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Web Resources